Skip to nav Skip to content

Adrenal carcinoma clinical trials offer unique opportunities to certain patients who are diagnosed with adrenal cancer, allowing participants to benefit from promising new therapies before those options become available in other settings. These groundbreaking studies are also designed to provide researchers with critical information about the effectiveness of new chemotherapy drugs and drug combinations, radiation delivery methods, surgical techniques and other approaches that can potentially be used to prevent, detect or treat adrenal gland cancer.

The progress of each patient who elects to participate in a clinical trial is closely monitored throughout the process. For instance, if at any point a patient’s treatment team determines that a different approach may be more beneficial to the patient, the patient’s treatment plan can be revised accordingly. Alternatively, a patient can choose to withdraw from a clinical trial at any time and for any reason (or no reason at all).

After an adrenal cancer clinical trial is completed and the results are compiled, the outcome is compared to that of currently available treatments. If the subject of the trial is found to have performed better than the current standard of care (or to have produced fewer side effects), the standard of care may be updated to incorporate the new treatment. In this way, adrenal carcinoma clinical trials can potentially enhance outcomes and quality of life and reduce recurrence for all current and future patients who are diagnosed with an adrenal gland tumor.

Why might a patient consider participating in a clinical trial?

When adrenal carcinoma clinical trials are recommended, the decision on whether or not to participate is complex, multi-faceted and highly personal. Some positive aspects of participation that a patient might consider include:

  • The treatment under study may be the best option available for the patient, offering the possibility of a better outcome or fewer side effects than the current standard of care.
  • A multispecialty team of experts closely monitors each clinical trial participant, continually evaluating his or her progress and fine-tuning his or her treatment as appropriate.
  • A participant can find personal satisfaction in the knowledge that he or she is contributing personally to the advancement of medical science and survival rates.

At Moffitt Cancer Center, we firmly believe that clinical trials are at the heart of all medical advances. Taking a unique “bench-to-bedside” approach, our dedicated team of scientists is working hard to quickly translate new research findings into tangible benefits for patients who are diagnosed with an adrenal tumor. To do so, we conduct extensive adrenal carcinoma clinical trials, which provide an essential link between our laboratories and our patients. Every day, Moffitt takes a few more steps forward in the ongoing fight against cancer.

If you’d like to receive information about the adrenal carcinoma clinical trials that are currently accepting new patients at Moffitt, our adrenal gland cancer experts can provide individualized guidance to help you find the best treatment option for you. To learn more, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form. We do not require referrals.